其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Quinolinic Acid CAS Registry Number: 89-00-9 吡啶-2,3-二羧酸

CAS Name: 2,3-Pyridinedicarboxylic acid
Percent Composition: C 50.31%, H 3.02%, N 8.38%, O 38.29%
Literature References: Metabolite of tryptophan, q.v. Prepn: S. Hoogewerff, W. A. van Dorp, Ber. 12, 747 (1879); W. Koenigs, ibid. 983; O. Fischer, E. Renouf, ibid. 17, 755 (1884); E. Sucharda, ibid. 58B, 1727 (1925); V. Yu. Stiks, S. A. Bulgach, ibid. 65B, 11 (1932); A. F. Lindenstruth, C. A. VanderWerf, J. Am. Chem. Soc. 71, 3020 (1949). Metabolism studies: L. M. Henderson et al., J. Biol. Chem. 181, 667, 677, 687, 731 (1949); H. P. Sarett, ibid. 193, 627 (1951). Neuroexcitatory activity and possible role in neurodegenerative disorders: R. Schwarcz et al., Science 219, 316 (1983).

Aluminum Tris(8-hydroxyquinoline) CAS Registry Number: 2085-33-8 8-羟基喹啉铝

CAS Name: Tris(8-quinolinolato-kN1,kO8)aluminum
Additional Names: tris(8-hydroxyquinoline)aluminium; Alq3
Percent Composition: C 70.59%, H 3.95%, Al 5.87%, N 9.15%, O 10.45%
Literature References: Metal chelate; fluorescent solid-state material for organic light-emitting devices (OLED). Prepn: R. Berg, Z. Anal. Chem. 71, 369 (1927); I. M. Kolthoff, E. B. Sandell, J. Am. Chem. Soc. 50, 1900 (1928); of analogs: H. Jang et al., Synth. Metals 121, 1667 (2001); of solid state: A. K. Saxena, Synth. React. Inorg. Met.-Org. Chem. 29, 1747 (1999). Exists as two geometric isomers mer- and fac- with several crytalline forms. Crystal structure and optical properties of a, b, and g-forms: M. Brinkmann et al., J. Am. Chem. Soc. 122, 5147 (2000); of blue luminescent d-form: M. Cölle et al., Adv. Funct. Mater. 13, 108 (2003). Photoemission at thin-film faces: W. Zhao et al., Chem. Mater. 16, 750 (2004). Reliability and degradation study: Z. D. Popovic, H. Aziz, IEEE J. Sel. Top. Quantum Electron. 8, 362 (2002). Use in OLEDs: C. W. Tang, S. A. VanSlyke, Appl. Phys. Lett. 51, 913 (1987); G. Baldacchini et al., Proc. 149th Int. School Phys. Enrico Fermi Rome 2002 561-567; as functionalized polymer: A. Meyers, M. Werk, Macromolecules 36, 1766 (2003). Review as emitting material for electroluminescence: C. H. Chen, J. Shi, Coord. Chem. Rev. 171, 161-174 (1998).

Rostaporfin CAS Registry Number: 284041-10-7 锡,二氯[rel-乙基(18R,19S)-3,4,20,21-四氢-4,9,14,19-四乙基-18,19-二氢-3,8,13,18-四甲基-20-福宾羧酸(2-)-kN23,kN24,kN25,kN26]-, (OC-6-13)-

CAS Name: (OC-6-13)-Dichloro[rel-ethyl (18R,19S)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kN23,kN24,kN25,kN26]tin
Additional Na...
Literature References: Metallopurpurin photosensitizer for photodynamic therapy. Prepn: A. R. Morgan et al., SPIE 847, 172 (1987); eidem, Cancer Res. 48, 194 (1988). Pharmacokinetics in dogs and rats: D. L. Frazier et al., J. Vet. Pharmacol. Ther. 15, 275 (1992). Intracranial tissue uptake and specificity: L. Lilge, B. C. Wilson, J. Clin. Laser Med. Surg. 16, 81 (1998). Photophysical properties: B. W. Pogue et al., Photochem. Photobiol. 68, 809 (1998). Clinical evaluation in cutaneous metastatic breast cancer: T. S. Mang et al., Cancer J. Sci. Am. 4, 378 (1998). Review of clinical development in wet age-related macular degeneration: D. W. C. Hunt, IDrugs 5, 180-186 (2002).

Ibutilide CAS Registry Number: 122647-31-8 伊布利特

CAS Name: N-[4-[4-(Ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide
Percent Composition: C 62.46%, H 9.44%, N 7.28%, O 12.48%, S 8.34%
Literature References: Methanesulfonanilide antiarrhythmic agent; prolongs myocardial action potential duration, predominantly by activation of slow inward sodium current. Prepn: J. B. Hester, EP 164865; idem, US 5155268 (1985, 1992 both to Upjohn); idem et al., J. Med. Chem. 34, 308 (1991). HPLC determn of enantiomers: C. L. Hsu, R. R. Walters, J. Chromatogr. B 667, 115 (1995); determn of racemate in plasma: L. Tian et al., J. Chromatogr. B 816, 81 (2005). Review of electrophysiology and pharmacology: G. V. Naccarelli et al., Am. J. Cardiol. 78, Suppl. 8A, 12-16 (1996); of pharmacology and clinical potential: R. H. Foster et al., Drugs 54, 312-330 (1997). Clinical trial in atrial flutter or fibrillation: B. S. Stambler et al., Circulation 94, 1613 (1996); J. T. VanderLugt et al., ibid. 100, 369 (1999); in elderly patients: R. M. Gowda et al., Am. J. Ther. 11, 95 (2004).

Cyprodinil CAS Registry Number: 121552-61-2 嘧菌环胺

CAS Name: 4-Cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine
Additional Names: N-(4-cyclopropyl-6-methylpyrimidin-2-yl)aniline; 2-phenylamino-4-methyl-6-cyclopropylpyrimidineTrademarks: Chorus (S...
Literature References: Methionine biosynthesis inhibitor. Prepn: A. Hubele, EP 310550; idem, US 5153200 (1989, 1992 both to Ciba-Geigy). Comprehensive description: U. J. Heye et al., Crop Prot. 13, 541-549 (1994). Mechanism of action: P. Masner et al., Pestic. Sci. 42, 163 (1994). Review of field trials: N. J. Leadbitter et al., Br. Crop Prot. Counc. Monogr. 57, 73-78 (1994).

Pentoxifylline CAS Registry Number: 6493-05-6 己酮可可碱

CAS Name: 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione
Additional Names: 1-(5-oxohexyl)theobromine; 1-(5-oxohexyl)-3,7-dimethylxanthine; 3,7-dimethyl-1-(5-oxohexyl)-1H,3H-purin-2...
Literature References: Methylxanthine derivative that improves blood flow by decreasing blood viscosity. Identity as a metabolite of pentifylline, q.v.: Mohler et al., Arch. Pharm. 299, 448 (1966); Mohler et al., Arzneim.-Forsch. 16, 1524 (1966). Prepn: NL 6511581; Mohler et al., DE 1235320; eidem, US 3422107 (1966, 1967, 1969 all to Chem. Werke Albert). Series of articles on chemistry, pharmacology and clinical trials: Arzneim.-Forsch. 21, 1159-1177 (1971). Toxicity data: K. Popendiker et al., ibid. 1160. Review of hemorheologic properties and use in cerebrovascular disease: R. Müller, F. Lehrach, Curr. Med. Res. Opin. 7, 253-263 (1981); of pharmacology and therapeutic uses: A. Ward, S. P. Clissold, Drugs 34, 50-97 (1987); C. P. Samlaska, E. A. Winfield, J. Am. Acad. Dermatol. 30, 603-621 (1994).

Lisofylline CAS Registry Number: 100324-81-0 利索茶碱

CAS Name: 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione
Additional Names: 1-[(R)-5-hydroxyhexyl]theobromine; 1-(5R-hydroxyhexyl)-3,7-dimethylxanthineTrademarks: ProTec (C...
Literature References: Methylxanthine that inhibits production of phosphatidic acid during the inflammatory response. Identification as metabolite of pentoxifylline: H.-J. Hinze et al., Arzneim.-Forsch. 22, 1144 (1972). Enantioselective process: W. Aretz et al., DE 3942872; eidem, US 5310666 (1991, 1994 both to Hoechst). Asymmetric synthesis: J. P. Klein et al., WO 9531450 (1995 to Cell Therapeutics). Study of mechanism of action in septic shock: G. C. Rice et al., Proc. Natl. Acad. Sci. USA 91, 3857 (1994). Enhancement of hematopoietic recovery following 5-fluorouracil treatment in mice: E. Clarke et al., Cancer Res. 56, 105 (1996).

Ixabepilone CAS Registry Number: 219989-84-1 伊沙匹隆

CAS Name: (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
Additional Names:...
Literature References: Microtubule stabilizing semisynthetic lactam analog of epothilone B, q.v. Prepn: G. D. Vite et al., WO 9902514; eidem, US 6605599 (1999, 2003 both to Bristol-Myers Squibb); R. M. Borzilleri et al., J. Am. Chem. Soc. 122, 8890 (2000). Antineoplastic activity in vitro and in vivo: F. Y. F. Lee et al., Clin. Cancer Res. 7, 1429 (2001). Clinical evaluation with estramustine in prostate cancer: J. E. Rosenberg et al., Cancer 106, 58 (2006). Clinical pharmacokinetics and evaluation in solid tumors: S. Mani et al., Clin. Cancer Res. 10, 1289 (2004). Clinical evaluation in breast cancer: J. A. Low et al., J. Clin. Oncol. 23, 2726 (2005); in prostate cancer: M. Hussain et al., ibid. 8724. Review of pharmacology and clinical development: N. Lin et al., Curr. Opin. Invest. Drugs 4, 746-756 (2003).

Titanium Tetraisopropoxide CAS Registry Number: 546-68-9 四异丙醇钛

Additional Names: Isopropyl titanate(IV); Titanium Isopropylate
Percent Composition: C 50.71%, H 9.93%, O 22.52%, Ti 16.84%
Literature References: Mild Lewis acid catalyst. Prepn: F. Bischoff, H. Adkins, J. Am. Chem. Soc. 46, 256 (1924). Vibrational spectra: P. D. Moran et al., Inorg. Chem. 37, 2741 (1998). Kinetic behavior in asymmetric epoxidation: S. S. Woodard et al., J. Am. Chem. Soc. 113, 106 (1991). Kinetics in prepn of titanium dioxide, q.v., thin films: V. Gourinchas-Courtecuisse et al., High Press. Chem. Eng. 1996, 133; G. A. Battiston et al., Metalurgija 8, 183 (2002); of sol-gel process: A. Soloviev et al., J. Mater. Sci. 38, 3315 (2003). Use as complexing agent in sol-gel process: B. Wang et al., Polym. Commun. 32, 400 (1991); H. Arce et al., Rev. Soc. Quim. Mex. 47, 73 (2003). Review as reagent in stereoselective synthesis: R. Mahrwald, J. Prakt. Chem. 341, 191-194 (1999); as catalyst: F. Lake, C. Moberg, Russ. J. Org. Chem. 39, 436-452 (2003). Brief review in a variety of organic syntheses: O. López, Synlett 2003, 2261-2262.

Lithium Tetrafluoroborate CAS Registry Number: 14283-07-9 四氟硼酸锂

Additional Names: Lithium fluoroboride; lithium fluoborate
Percent Composition: B 11.53%, F 81.06%, Li 7.40%
Literature References: Mild Lewis acid. Prepn: P. Baumgarten, W. Bruns, Ber. 72, 1753 (1939); I. Shapiro, H. G. Weiss, J. Am. Chem. Soc. 75, 1753 (1953). NMR structural study: E. C. Reynhardt, J. A. J. Lourens, J. Chem. Phys. 80, 6240 (1984); 19F NMR study of soln behavior: V. N. Plakhotnik et al., J. Fluorine Chem. 98, 133 (1999). Catalytic use in Diels-Alder reactions: D. A. Smith, K. N. Houk, Tetrahedron Lett. 32, 1549 (1991); J. S. Yadav et al., Synthesis 2001, 1065. Review of applications in organic synthesis: B. S. Babu, K. K. Balasubramanian, Acros Org. Acta 7, 1-3 (2000).